DecisionDx-UM

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Wednesday, February 28, 2024

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023.
  • DecisionDx-SCC test reports delivered in the quarter were 3,530, compared to 1,845 in the fourth quarter of 2022, an increase of 91%.
  • DecisionDx-UM test reports delivered in the quarter were 405, compared to 432 in the fourth quarter of 2022, a decrease of 6%.
  • Castle Biosciences will hold a conference call on Wednesday, Feb. 28, 2024, at 4:30 p.m. Eastern time to discuss its fourth quarter and full-year 2023 results and provide a corporate update.

MCI Onehealth Partners with uMed to Accelerate Clinical Research

Retrieved on: 
Thursday, March 9, 2023

“MCI’s collaboration with uMed will open a new subset of research that emphasizes real-world evidence and patient-reported information.

Key Points: 
  • “MCI’s collaboration with uMed will open a new subset of research that emphasizes real-world evidence and patient-reported information.
  • MCI firmly believes that patient-facing technology is a core component for increasing access to healthcare and for making care more personalized,” said Dr. Alexander Dobranowski, founder and CEO of MCI.
  • “MCI is already uniquely positioned in that we use technology to screen clinical data efficiently and compliantly to flag patients as potential participants for research trials.
  • MCI’s audience for clinical insights continues to grow in Canada and the US and will further benefit from collaboration with international leader uMed.

Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program

Retrieved on: 
Thursday, October 27, 2022

The studies are part of the Companys ongoing collaboration with the National Cancer Institute (NCI) to link DecisionDx-Melanoma and DecisionDx-UM clinical testing data with data from the Surveillance, Epidemiology and End Results (SEER) Programs registries on CM and UM cases, respectively.

Key Points: 
  • The studies are part of the Companys ongoing collaboration with the National Cancer Institute (NCI) to link DecisionDx-Melanoma and DecisionDx-UM clinical testing data with data from the Surveillance, Epidemiology and End Results (SEER) Programs registries on CM and UM cases, respectively.
  • The data were shared in poster presentations at the 19th International Congress of the Society for Melanoma Research (SMR) in Edinburgh, United Kingdom.
  • In the study, DecisionDx-Melanoma was a statistically significant and independent predictor of melanoma-specific survival (MSS), consistent with previously published retrospective and prospective studies.
  • Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make.

 Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day

Retrieved on: 
Tuesday, September 20, 2022

During its Investor Day today, senior leaders of Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present the Companys foundational guideposts exceptional employees, continuous evolution and improvement, and customer and solution centric as well as three-year financial targets.

Key Points: 
  • During its Investor Day today, senior leaders of Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present the Companys foundational guideposts exceptional employees, continuous evolution and improvement, and customer and solution centric as well as three-year financial targets.
  • Prepared remarks for Castles Investor Day will begin today at 4:00 p.m. Eastern time, followed by a Question & Answer session.
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association

Retrieved on: 
Tuesday, September 13, 2022

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received an AZBio Fast Lane Award from the Arizona Bioindustry Association (AZBio).

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received an AZBio Fast Lane Award from the Arizona Bioindustry Association (AZBio).
  • Castle Biosciences is working to transform how diseases are managed with the goal of making life better for patients, said Joan Koerber-Walker, president and chief executive officer of AZBio.
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
    For the last 19 years, the Arizona Bioindustry Association (AZBio) has supported life science innovation and life science innovators in Arizona.

Castle Biosciences to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, September 1, 2022

A live audio webcast of the Companys presentation will be available on Castle Biosciences website at https://ir.castlebiosciences.com/events-presentations/default.aspx .

Key Points: 
  • A live audio webcast of the Companys presentation will be available on Castle Biosciences website at https://ir.castlebiosciences.com/events-presentations/default.aspx .
  • Castle will also be available for one-on-one investor meetings during the 6th Annual Lake Street Best Ideas Growth (BIG6) Conference on Sept. 14, 2022.
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005116/en/

First of its kind patient cohort program announced at IPF-Summit

Retrieved on: 
Monday, August 29, 2022

UK-based company uMed announced the launch of the Access-ILD/PF Cohort at the sixth annual Idiopathic Pulmonary Fibrosis (IPF) Summit in Boston.

Key Points: 
  • UK-based company uMed announced the launch of the Access-ILD/PF Cohort at the sixth annual Idiopathic Pulmonary Fibrosis (IPF) Summit in Boston.
  • Our pioneering platform is designed to solve the challenges that researchers and patients are facing delays in new therapies.
  • With such a deep pipeline and more trials on the horizon, there is a significant demand for patient participation.
  • This platform builds on the work we successfully initiated in the UK, with a goal of creating a global cohort to support multiple studies.

Castle Biosciences to Host Investor Day on Sept. 20, 2022

Retrieved on: 
Wednesday, August 24, 2022

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will host an Investor Day on Sept. 20, 2022.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will host an Investor Day on Sept. 20, 2022.
  • Castles Investor Day event is scheduled to begin at 4:00 p.m. EDT and conclude at 6:30 p.m. EDT, followed by a Question & Answer session.
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005090/en/

American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus

Retrieved on: 
Thursday, August 4, 2022

TissueCypher is Castles test for patients with BE that is designed to predict progression to high-grade dysplasia (HGD) and/or esophageal adenocarcinoma (EAC), a form of esophageal cancer.

Key Points: 
  • TissueCypher is Castles test for patients with BE that is designed to predict progression to high-grade dysplasia (HGD) and/or esophageal adenocarcinoma (EAC), a form of esophageal cancer.
  • The best practice advice article from the AGA, titled AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barretts Esophagus: Expert Review, was recently published online in Clinical Gastroenterology and Hepatology and can be viewed here .
  • Based on the published clinical data, the AGA agreed that TissueCypher may be beneficial as part of an improved care pathway for managing patients with BE.
  • The TissueCypher Barretts Esophagus test is Castles precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barretts esophagus (BE).

Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference

Retrieved on: 
Wednesday, August 3, 2022

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, Aug. 10, 2022, at 1:00 p.m. Eastern time.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, Aug. 10, 2022, at 1:00 p.m. Eastern time.
  • A live audio webcast of the Companys presentation will be available by visiting Castle Biosciences website at https://ir.castlebiosciences.com/events-presentations/default.aspx .
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005065/en/